News
Tabrecta Approved for METex14 Metastatic Non-Small Cell Lung Cancer
The Food and Drug Administration has granted accelerated approval to Tabrecta™ (capmatinib; Novartis).
Your search for non small cell lung cancer returned 67 results
Drugs in the Pipeline
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Drugs in the Pipeline
FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC
Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.
News
Cemiplimab Application for Advanced Cervical Cancer Withdrawn
The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.
Drugs in the Pipeline
Improved Overall Survival With Cemiplimab in Cervical Cancer Trial
The phase 3 trial evaluated the efficacy and safety of cemiplimab in women 18 years of age and older with recurrent or metastatic cervical cancer, including those with either squamous cell carcinoma or adenocarcinoma.
News
Xalkori Approved for Anaplastic Large Cell Lymphoma in Children, Young Adults
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
News
Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
News
New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
News
Tecentriq Gains Approval for Additional Lung Cancer Indication
The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.
News
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
